<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003989</url>
  </required_header>
  <id_info>
    <org_study_id>RBM_CLL_2012-7</org_study_id>
    <nct_id>NCT02003989</nct_id>
  </id_info>
  <brief_title>Revealing Increased Axonal Loss in Treated HIV Patients</brief_title>
  <acronym>OCTIHIV</acronym>
  <official_title>Revealing Increased Axonal Loss in Treated HIV Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV patients may suffer sooner from aging than average population, including brain aging. Our&#xD;
      hypothesis is that if brain dysfunctions are explained by a quicker loss of neurons in HIV&#xD;
      patients, this loss could be detected earlier by a thinning down of retinal nerve fiber layer&#xD;
      (RNFL), compared to non HIV patients of the same age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to compare the thickness of the RNFL and the thickness of the RCGs&#xD;
      measured by spectral domain OCT between patients infected by HIV and patients of same age non&#xD;
      infected by HIV.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>thickness of the RNFL and the RCGs measured by spectral domain OCT, between the two groups of patients</measure>
    <time_frame>one day of examinations</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">156</enrollment>
  <condition>HIV Seropositivity</condition>
  <arm_group>
    <arm_group_label>patients</arm_group_label>
    <description>HIV patients infected for more than ten years with undetectable viral load, undergoing ophthalmologic examination and MRI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>non HIV patients (same gender and age) undergoing ophthalmologic examination and MRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ophthalmologic examination and MRI</intervention_name>
    <description>thorough investigation of patients, not included in usual care.</description>
    <arm_group_label>control</arm_group_label>
    <arm_group_label>patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HIV patients infected for at least 10 years with undetectable viral load, selected among&#xD;
        infectious disease outpatients (consecutive exhaustive recruitment)&#xD;
&#xD;
        non HIV patients matched for age and gender&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infection known since at least 10 years&#xD;
&#xD;
          -  viral load undetectable under ARV treatment since at least 5 years, whatever the type&#xD;
             of ARV&#xD;
&#xD;
          -  lymphocytes CD4 &gt; 350, whatever the CD4 nadir&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of ocular pathology, eye surgery, or intraocular injection&#xD;
&#xD;
          -  Familial History of glaucoma&#xD;
&#xD;
          -  ametropia (&gt;3 dioptres on the sphere and &gt;1,5 dioptres on the cylinder)&#xD;
&#xD;
          -  known neurological pathology, active or former&#xD;
&#xD;
          -  History of ethambutol or synthetic antimalarial drug consumption&#xD;
&#xD;
          -  History of chemotherapy&#xD;
&#xD;
          -  Active and regular use of drugs&#xD;
&#xD;
          -  non-weaned chronic alcoholism&#xD;
&#xD;
          -  contra indication to MRI&#xD;
&#xD;
          -  diabetes&#xD;
&#xD;
          -  cognitive disorders (MoCA&lt;26)&#xD;
&#xD;
          -  non covered by health insurance&#xD;
&#xD;
          -  patient under legal protection&#xD;
&#xD;
          -  pregnant or breast-feeding woman&#xD;
&#xD;
          -  Non inclusion criteria for control patients: known HIV infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CÃ©dric LAMIREL, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique Adolphe de Rothschild</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe GIRARD, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Mutualiste Montsouris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine MOULIGNIE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique Adolphe de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation OPH A de Rothschild</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>October 20, 2016</last_update_submitted>
  <last_update_submitted_qc>October 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

